Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES BERGVIK SKOG AB IN CONJUNCTION WITH A CO-OPERATION WITH VATTENFALL VINDKRAFT AB CONCERNING SVARTNÄS WIND FARM
Mandate

VINGE ADVISES BERGVIK SKOG AB IN CONJUNCTION WITH A CO-OPERATION WITH VATTENFALL VINDKRAFT AB CONCERNING SVARTNÄS WIND FARM

November 27, 2014

Vinge has advised Bergvik Skog AB in conjunction with its execution of a co-operation agreement relating to Svartnäs wind farm with Vattenfall Vindkraft AB. The agreement entails that Vattenfall will take over the future project planning phase of the wind farm and Vattenfall has also been granted an exclusive right to acquire the project, which is based on a permit issued to Bergvik Skog AB in January 2014 to construct a total of 53 wind turbines at the Svartnäs wind farm. The investment in Svartnäs wind farm will be in the region of SEK 1-1.5 billion and the farm is estimated to become operational in 2017.

Vinge’s team consisted of responsible partner Fabian Ekeblad, partner Thomas Sjöberg and associates Johan Cederblad and Malin Buch.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024